Preliminary results of a phase I study: A chimeric monoclonal anti IL-6 antibody CNTO 328 in combination with docetaxel in patients with hormone refractory prostate cancer

被引：0
|
作者：
Hudes, G. R.
Nanus, D.
Qi, M.
Prabhakar, U.
Corringham, R.
Jiao, Q.
Eisenberger, M.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Cornell Univ, New York Presbyterian Hosp, New York, NY 10021 USA
[3] Centocor Inc, Malvern, PA 19355 USA
[4] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15521
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preliminary results of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb), in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma
    Manges, Robert F.
    Sutherland, Heather J.
    Jagannath, Sundar
    Orlowski, Robert Z.
    La Police, David
    DeWitte, Mark
    Lang, Zhihui
    Corringham, Robert E.
    Rossi, Jean Francois
    BLOOD, 2007, 110 (11) : 358A - 359A
  • [2] A phase I study of CNTO328, an anti-interleukin (IL)-6 monoclonal antibody combined with docetaxel in subjects with metastatic castration-resistant prostate cancer (CRPC)
    Hudes, G.
    Tagawa, S.
    Whang, Y.
    Qi, M.
    Qin, X.
    Puchalski, T.
    Prabhakar, U.
    O'Brien, K.
    Eisenberger, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma
    Rossi, Jean-Francois
    Manges, Robert F.
    Sutherland, Heather J.
    Jagannath, Sundar
    Voorhees, Peter
    Sonneveld, Pieter
    Delforge, Michel
    Pegourie, Brigitte
    Alegre, Adrian
    de la Rubia, Javier
    La Police, David
    Bandekar, Rajesh
    Xie, Hong
    Orlowski, Robert Z.
    BLOOD, 2008, 112 (11) : 320 - 321
  • [4] Phase I study of CNTO 95, a fully human monoclonal antibody to αv integrins, docetaxel, and prednisone in hormone refractory prostate cancer patients (HRPCP)
    Chu, F. M.
    Picus, J.
    Mata, M.
    Kopacynski, C.
    Foster, B.
    Lang, Z.
    Beckman, R. A.
    Dreicer, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM)
    Voorhees, P. M.
    Manges, R. F.
    Somlo, G.
    Lentzsch, S.
    Jagannath, S.
    Sonneveld, P.
    Frank, R. C.
    Zweegma, S.
    Wijermans, P. W.
    Thomas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
    Rossi, J-F
    Negrier, S.
    James, N. D.
    Kocak, I.
    Hawkins, R.
    Davis, H.
    Prabhakar, U.
    Qin, X.
    Mulders, P.
    Berns, B.
    BRITISH JOURNAL OF CANCER, 2010, 103 (08) : 1154 - 1162
  • [7] A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
    J-F Rossi
    S Négrier
    N D James
    I Kocak
    R Hawkins
    H Davis
    U Prabhakar
    X Qin
    P Mulders
    B Berns
    British Journal of Cancer, 2010, 103 : 1154 - 1162
  • [8] Complete Remission Achieved With Single Agent CNTO 328, an Anti-IL-6 Monoclonal Antibody, in Relapsed and Refractory Myeloma
    Chari, Ajai
    Pri-Chen, Hadass
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (03): : 333 - 337
  • [9] CNTO 328, a Monoclonal Antibody to Interleukin-6. Is Active as a Single Agent in Castleman's Disease: Preliminary Results of a Phase I Study.
    Van Rhee, Frits
    Fayad, Luis
    Voorhees, Peter
    Furiman, Richard R.
    Borghaei, Hossein
    Lonial, Sagar
    Sokol, Lubomir
    Crawford, Julie
    Cornfield, Mark
    Qi, Ming
    Herring, Jennifer
    Qin, Xiang
    Kurzrock, Razelle
    BLOOD, 2008, 112 (11) : 371 - 371
  • [10] Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
    Fizazi, K.
    De Bono, J. S.
    Flechon, A.
    Heidenreich, A.
    Voog, E.
    Davis, N. B.
    Qi, Ming
    Bandekar, R.
    Vermeulen, J. T.
    Cornfeld, M.
    Hudes, G. R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (01) : 85 - 93
12345